Acorda plans to sell 3.38 million shares
-
- June
- 4
Acorda Therapeutics Inc., a biotechnology company based in Hawthorne, announced today that it plans to sell 3.38 million shares of common stock in a public offering. Final terms of the offering will be disclosed in a future filing with the Securities and Exchange Commission, the company said. Acorda intends to use proceeds from the offering to complete a second Phase 3 trial of Fampridine-SR, a treatment for multiple sclerosis, and other business purposes. Banc of America Securities LLC and Deutsche Bank Securities are managing the offering, Acorda said.
This entry was posted
on Monday, June 4th, 2007 at 4:24 pm by David Schepp.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
